Rutgers Cancer Institute Single-Cell Study Launches Center for Precision Medicine

New Brunswick N. J. July 31 2018 – Rutgers Cancer Institute researchers have launched a unique single-cell screening platform using a piece of graphene. The platform is driven by hydrogen peroxide – a patented nanoeutrochemical therapy approach allowing us to better view single cells in tissue.

Rutgers Cancer Institute researchers will use HL-60-test – which combines advanced optical and cell signaling technology to photograph single cells in samples of mucosal tissues from patients. Existing HD-risk patients will be patient controlled so the deployment of the platform will be controlled by the patients.

The small package 10-gram membranous material will be induced to glow prior to primary tumor growth – providing a fully-user selectable LED-based system for shining at every source of medical or surgical use. The LED system will also enable programmable LED lighting in any environmental setting allowing for bioregulation. All approved components will be constructed using certified manufacturing processes in the US and worldwide.

Artists illustration of the HL-60-test platform.

In a bioregulation system dubbed HL-60-test the LED system will guide the alignment of the pore or opening of the bladder. The pore provides a solid connection between the pH — often the lower urinary tract — and the capillary — the tube that draws urine and excretes waste. This is accomplished using slim-backed capillaries by the renal epithelium.

Jinghai Feng PhD FRCPB Associate Director and Associate Dean Rutgers Department of Biochemistry and Molecular Biophysics who developed the HL-60-test platform.

The single cell application will be supported with BLOOD88 a High-throughput rapid-dot-matrix non-invasive blood test. BLOOD88 is engineered from molecular interactions between cell-density changing proteins hydrogels and biological biomarkers. Its high throughput over a small range of inputs will make it ideal for a wide range of clinical applications such as drug discovery diagnostics and screening.

With this platform researchers will develop a gene-matched 10-dimensional array of micro-mucosal columns – along with the use of expanded-tip imaging – for single cell diagnosis tracking of tumors in the body simple analysis using single cell crystallography and mapping of single cells using motility and electrochemistry and monitoring of blood cell function using magnetic resonance imaging.